Sevilla

• Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea … Ended recruitment
  2024-514630-21-00 4 2022-08-11 HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
• A Study of an experimental drug, MK-2140 in combination with standard of care chemotherapy in participants with Diffuse Large B-Cell Lymphom … Ended recruitment
  2022-501380-40-00 4 2022-08-10 Diffuse large B-cell lymphoma (DLBCL)
• Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global Study Ended recruitment
  2024-516604-41-00 4 2022-08-08 Non-small Cell Lung Cancer
• A study to learn if Rozanolixizumab works and is safe over a long period in adults with relapsing myelin oligodendrocyte glycoprotein antibo … Ended recruitment
  2023-509237-39-00 5 2022-08-02 Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-A
• A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance … Ended recruitment
  2023-504996-26-00 5 2022-07-21 Metastatic Castration Resistant Prostate Cancer (mCRPC)
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer ( … Ended recruitment
  2023-509260-25-00 5 2022-07-12 Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
• An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered to Patients with Familial Chylomicronemia Syndrome (FCS) Ended recruitment
  2023-509029-29-00 5 2022-06-29 Familial Chylomicronemia Syndrome (FCS)
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended recruitment
  2023-505974-14-00 5 2022-06-23 Multiple Sclerosis (MS)
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509345-12-00 5 2022-06-22 Multiple Sclerosis
• GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t … Ended recruitment
  2023-504737-41-00 5 2022-06-10 Moderately to Severely Active Crohn's Disease
• A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended recruitment
  2023-505635-13-00 5 2022-06-10 Systemic lupus erythematosus
• A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias … Ended recruitment
  2024-513759-34-00 7 2022-05-31 Relapsed or Refractory Acute Leukemias
• A research study to evaluate the activity of Sotorasib for the treatment of patients with non-operable non-small cell lung cancer with a KRA … Ended recruitment
  2024-511268-10-00 4 2022-05-25 Unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cel
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• A study in patients with skin cancer Ended recruitment
  2024-516914-39-00 5 2022-04-27 Metastatic or unresectable melanoma
• A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarco … Ended recruitment
  2024-517528-20-00 4 2022-04-19 Unresectable or metastatic conventional chondrosarcoma
• A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) Ended recruitment
  2024-512745-16-00 5 2022-04-13 Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
• A Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non−Small-Cell Lung Ca … Ended recruitment
  2024-513225-23-00 4 2022-04-07 Non-small cell lung cancer
• Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended recruitment
  2023-506361-56-00 5 2022-04-01 Endometrial cancer
• A study to assess the Safety, Tolerability, Pharmacokinetics and Anti tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lun … Ended recruitment
  2024-512127-36-00 9 2022-03-31 Non-Small Cell Lung Cancer
• Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended recruitment
  2023-504597-37-00 5 2022-03-25 Focal segmental glomerulosclerosis
• An international randomized clinical study, measuring safety and effectiveness of basimglurant for the treatment of pain in patients with Tr … Ended recruitment
  2024-514497-41-00 10 2022-03-24 Trigeminal neuralgia
• Master Protocol for Avelumab Continuation Study. Ended recruitment
  2023-509466-38-00 5 2022-03-08 Cancer

Showing 1,009–1,032 of 1,630 trials